
## Martin O Savage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1390301/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Growth Hormone Receptor <i>(GHR)</i> 6Ω Pseudoexon Activation: A Novel Cause of Severe Growth Hormone Insensitivity. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e401-e416.	1.8	4
2	Patients' Perception of the Use of the EasyPodâ,,¢ Growth Hormone Injector Device and Impact on Injection Adherence: A Multi-Center Regional Study. Frontiers in Pediatrics, 2022, 10, 839278.	0.9	2
3	The Changing Face of Paediatric Human Growth Hormone Therapy. Endocrines, 2022, 3, 419-427.	0.4	Ο
4	Evaluating the sensitivity and specificity of the UK and Dutch growth referral criteria in predicting the diagnosis of pathological short stature. BMJ Paediatrics Open, 2022, 6, e001385.	0.6	0
5	The value of whole exome sequencing for genetic diagnosis in a patient with Bloom syndrome. Journal of Endocrinological Investigation, 2021, 44, 1331-1334.	1.8	6
6	The continuum between GH deficiency and GH insensitivity in children. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 91-99.	2.6	4
7	Growth failure: â€~idiopathic' only after a detailed diagnostic evaluation. Endocrine Connections, 2021, 10, R125-R138.	0.8	17
8	Genetic Characterization of Short Stature Patients With Overlapping Features of Growth Hormone Insensitivity Syndromes. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4716-e4733.	1.8	11
9	Digital Health for Supporting Precision Medicine in Pediatric Endocrine Disorders: Opportunities for Improved Patient Care. Frontiers in Pediatrics, 2021, 9, 715705.	0.9	15
10	Digital technologies to improve the precision of paediatric growth disorder diagnosis and management. Growth Hormone and IGF Research, 2021, 59, 101408.	0.5	11
11	Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 817-835.	2.6	23
12	GH Resistance Is a Component of Idiopathic Short Stature: Implications for rhGH Therapy. Frontiers in Endocrinology, 2021, 12, 781044.	1.5	5
13	Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management. Clinical Endocrinology, 2020, 92, 98-108.	1.2	20
14	GHR gene transcript heterogeneity may explain phenotypic variability in GHR pseudoexon (6Î <sup>-</sup> ) patients. Endocrine Connections, 2020, 9, 211-222.	0.8	4
15	Managing Paediatric Growth Disorders: Integrating Technology Into a Personalised Approach. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2020, 12, 225-232.	0.4	6
16	Pediatric Cushing Disease. , 2019, , 444-453.		0
17	Nonclassical GH Insensitivity: Characterization of Mild Abnormalities of GH Action. Endocrine Reviews, 2019, 40, 476-505.	8.9	32
18	Achieving Optimal Short- and Long-term Responses to Paediatric Growth Hormone Therapy. JCRPE Journal of Clinical Research in Pediatric Endocrinology, 2019, 11, 329-340.	0.4	16

#	Article	IF	CITATIONS
19	SUN-454 Rationale and Methods for a Phase II Trial Evaluating Osilodrostat in Pediatric Patients with Cushing's Disease. Journal of the Endocrine Society, 2019, 3, .	0.1	ο
20	Phenotypic spectrum and responses to recombinant human IGF1 (rhIGF1) therapy in patients with homozygous intronic pseudoexon growth hormone receptor mutation. European Journal of Endocrinology, 2018, 178, 481-489.	1.9	17
21	The growth hormone–insulin-like growth factor-I axis in the diagnosis and treatment of growth disorders. Endocrine Connections, 2018, 7, R212-R222.	0.8	81
22	Growth Hormone Insensitivity. , 2018, , 81-93.		0
23	Cushing's syndrome in infancy due to ectopic ACTH secretion by a sacro-coccygeal teratoma. Journal of Pediatric Endocrinology and Metabolism, 2017, 30, 475-478.	0.4	6
24	Whole-exome sequencing gives additional benefits compared to candidate gene sequencing in the molecular diagnosis of children with growth hormone or IGF-1 insensitivity. European Journal of Endocrinology, 2017, 177, 485-501.	1.9	30
25	Novel Dominant-Negative GH Receptor Mutations Expands the Spectrum of GHI and IGF-I Deficiency. Journal of the Endocrine Society, 2017, 1, 345-358.	0.1	26
26	Early Detection, Referral, Investigation, and Diagnosis of Children with Growth Disorders. Hormone Research in Paediatrics, 2016, 85, 325-332.	0.8	35
27	Diagnosis and management of growth disorders in Gulf Cooperation Council (GCC) countries: Current procedures and key recommendations for best practice. International Journal of Pediatrics and Adolescent Medicine, 2016, 3, 91-102.	0.5	8
28	Long-term outcomes of children treated for Cushing's disease: a single center experience. Pituitary, 2016, 19, 612-624.	1.6	29
29	Investigation for Paediatric Cushing's Syndrome Using Twenty-Four-Hour Urinary Free Cortisol Determination. Hormone Research in Paediatrics, 2016, 86, 21-26.	0.8	14
30	Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2807-2831.	1.8	899
31	Genetic characterisation of a cohort of children clinically labelled as GH or IGF1 insensitive: diagnostic value of serum IGF1 and height at presentation. European Journal of Endocrinology, 2015, 172, 151-161.	1.9	29
32	MANAGEMENT OF ENDOCRINE DISEASE: Paediatric Cushing's disease. European Journal of Endocrinology, 2015, 173, R35-R45.	1.9	40
33	Heterogeneity of the growth phenotype and birth size in acid-labile subunit (ALS) deficiency. Journal of Endocrinological Investigation, 2015, 38, 407-412.	1.8	12
34	Fundamental principles of clinical and biochemical evaluation underlie the diagnosis and therapy of Cushing's syndrome. Journal of Pediatric Endocrinology and Metabolism, 2014, 27, 1029-1031.	0.4	4
35	Endonasal endoscopic transsphenoidal pituitary surgery: early experience and outcome in paediatric <scp>C</scp> ushing's disease. Clinical Endocrinology, 2014, 80, 270-276.	1.2	38
36	Phenotypes, Investigation and Treatment of Primary IGF-1 Deficiency. Endocrine Development, 2013, 24, 138-149.	1.3	18

#	Article	IF	CITATIONS
37	Insulin-Like Growth Factors, Nutrition and Growth. World Review of Nutrition and Dietetics, 2013, 106, 52-59.	0.1	37
38	Identification and management of poor response to growthâ€promoting therapy in children with short stature. Clinical Endocrinology, 2012, 77, 169-181.	1.2	59
39	Pediatric Cushing′s disease: Management Issues. Indian Journal of Endocrinology and Metabolism, 2012, 16, 171.	0.2	26
40	The variability of responses to growth hormone therapy in children with short stature. Indian Journal of Endocrinology and Metabolism, 2012, 16, 178.	0.2	20
41	Le continuum des résistances à l'hormone de croissance : du retard statural idiopathique au syndrome de Laron. , 2012, , 187-201.		Ο
42	IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Practice and Research in Clinical Endocrinology and Metabolism, 2011, 25, 181-190.	2.2	89
43	Genetic Defects in the Growth Hormone?IGF-I Axis Causing Growth Hormone Insensitivity and Impaired Linear Growth. Frontiers in Endocrinology, 2011, 2, 95.	1.5	29
44	Comparisons in the epidemiology, diagnostic features and cure rate by transsphenoidal surgery between paediatric and adult-onset Cushing's disease. European Journal of Endocrinology, 2011, 164, 667-674.	1.9	93
45	Use of Intravenous Etomidate to Control Acute Psychosis Induced by the Hypercortisolaemia in Severe Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2011, 75, 441-446.	0.8	28
46	Evidence for a Continuum of Genetic, Phenotypic, and Biochemical Abnormalities in Children with Growth Hormone Insensitivity. Endocrine Reviews, 2011, 32, 472-497.	8.9	171
47	Diagnosis and Treatment of Pediatric Cushing's Disease. Growth Hormone, 2011, , 197-210.	0.2	Ο
48	The continuum of growth hormone–IGFâ€I axis defects causing short stature: diagnostic and therapeutic challenges. Clinical Endocrinology, 2010, 72, 721-728.	1.2	79
49	Diagnosis, management and therapeutic outcome in prepubertal Cushing's disease. European Journal of Endocrinology, 2010, 162, 603-609.	1.9	28
50	Acid-Labile Subunit Deficiency and Growth Failure: Description of Two Novel Cases. Hormone Research in Paediatrics, 2010, 73, 328-334.	0.8	23
51	Identification and characterisation of a novel GHR defect disrupting the polypyrimidine tract and resulting in GH insensitivity. European Journal of Endocrinology, 2010, 162, 37-42.	1.9	16
52	Growthâ€promoting Hormone Therapy in Inflammatory Bowel Disease. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, S135-6.	0.9	4
53	Special Aspects of Cushing's Syndrome: Childhood. , 2010, , 273-282.		0
54	Pathophysiology, assessment and management of the child with growth hormone resistance. Pediatric Endocrinology Reviews, 2010, 7, 347-56.	1.2	2

#	Article	IF	CITATIONS
55	Phenotypic Aspects of Growth Hormone- and IGF-I-Resistant Syndromes. Endocrine Development, 2009, 14, 143-150.	1.3	4
56	Diagnosis and Treatment of Cushing's Disease in Children. Endocrine Development, 2009, 17, 134-145.	1.3	4
57	Should idiopathic short stature be treated with growth hormone?. Nature Reviews Endocrinology, 2009, 5, 148-149.	4.3	7
58	Expanding the Spectrum of Mutations in GH1 and GHRHR: Genetic Screening in a Large Cohort of Patients with Congenital Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3191-3199.	1.8	103
59	Growth and body composition at diagnosis and postcure in children with Cushing's syndrome. Pediatric Health, 2009, 3, 13-18.	0.3	Ο
60	Abnormal growth in noonan syndrome: the challenge of optimal therapy. Pediatric Endocrinology Reviews, 2009, 6 Suppl 4, 523-8.	1.2	1
61	Advances in the Management of Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2008, 69, 327-333.	0.8	13
62	Diagnosis of pediatric Cushing's syndrome—which test is best?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 76-77.	2.9	1
63	The Diagnosis of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1526-1540.	1.8	2,131
64	Idiopathic short stature: Management and growth hormone treatment. Growth Hormone and IGF Research, 2008, 18, 111-135.	0.5	69
65	Idiopathic short stature: Definition, epidemiology, and diagnostic evaluation. Growth Hormone and IGF Research, 2008, 18, 89-110.	0.5	197
66	Consensus Statement on the Diagnosis and Treatment of Children with Idiopathic Short Stature: A Summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4210-4217.	1.8	571
67	Abnormal Growth in Noonan Syndrome: Genetic and Endocrine Features and Optimal Treatment. Hormone Research, 2008, 70, 129-136.	1.8	30
68	Work-up and management of paediatric Cushing's syndrome. Current Opinion in Endocrinology, Diabetes and Obesity, 2008, 15, 346-351.	1.2	44
69	Long-term anterior pituitary function in patients with paediatric Cushing's disease treated with pituitary radiotherapy. European Journal of Endocrinology, 2007, 156, 477-482.	1.9	37
70	An Intronic Growth Hormone Receptor Mutation Causing Activation of a Pseudoexon Is Associated with a Broad Spectrum of Growth Hormone Insensitivity Phenotypes. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 655-659.	1.8	51
71	Idiopathic short stature: will genetics influence the choice between GH and IGF-I therapy?. European Journal of Endocrinology, 2007, 157, S33-S37.	1.9	24
72	Factors Influencing Skeletal Maturation at Diagnosis of Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2007, 68, 231-235.	0.8	20

#	Article	IF	CITATIONS
73	Management of Chronic Systemic Diseases. Hormone Research in Paediatrics, 2007, 68, 112-112.	0.8	Ο
74	Final Height in Patients with Idiopathic Short Stature and High Growth Hormone Responses to Stimulation Tests. Hormone Research in Paediatrics, 2007, 67, 224-230.	0.8	2
75	Defects in growth hormone receptor signaling. Trends in Endocrinology and Metabolism, 2007, 18, 134-141.	3.1	134
76	Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances. Trends in Endocrinology and Metabolism, 2007, 18, 167-174.	3.1	120
77	Clinical and endocrine features and long-term outcome of Graves' disease in early childhood. Journal of Endocrinological Investigation, 2007, 30, 388-392.	1.8	25
78	Excellent growth response to growth hormone therapy in a child with PTPN11-negative Noonan syndrome and features of growth hormone resistance. Journal of Endocrinological Investigation, 2007, 30, 439-441.	1.8	2
79	Growth Hormone Insensitivity and Severe Short Stature in Siblings: A Novel Mutation at the Exon 13 Junction of the <i>STAT5b</i> Gene. Hormone Research in Paediatrics, 2007, 68, 218-224.	0.8	49
80	Pediatric Cushing's syndrome: clinical features, diagnosis, and treatment. Arquivos Brasileiros De Endocrinologia E Metabologia, 2007, 51, 1261-1271.	1.3	34
81	Abnormal puberty in paediatric Cushing's disease: relationship with adrenal androgen, sex hormone binding globulin and gonadotrophin concentrations. Clinical Endocrinology, 2007, 66, 838-843.	1.2	48
82	Diagnosis and treatment of pediatric Cushing's disease. Pituitary, 2007, 10, 365-371.	1.6	23
83	Adrenal disorders. , 2007, , .		Ο
84	Linear growth and body mass index in pediatric patients with Cushing's disease or simple obesity. Journal of Endocrinological Investigation, 2006, 29, 885-887.	1.8	33
85	Pharmacokinetic Studies of Recombinant Human Insulin-Like Growth Factor I (rhIGF-I)/rhIGF-Binding Protein-3 Complex Administered to Patients with Growth Hormone Insensitivity Syndrome. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 1246-1253.	1.8	45
86	Clinical Features Affecting Final Adult Height in Patients With Pediatric-Onset Crohn's Disease. Pediatrics, 2006, 118, 124-129.	1.0	180
87	A 36 residues insertion in the dimerization domain of the growth hormone receptor results in defective trafficking rather than impaired signaling. Journal of Endocrinology, 2006, 188, 251-261.	1.2	29
88	Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 395-407.	2.9	78
89	The Discriminatory Value of the Low-Dose Dexamethasone Suppression Test in the Investigation of Paediatric Cushing's Syndrome. Hormone Research in Paediatrics, 2006, 65, 159-162.	0.8	26
90	The role of corticotrophin-releasing hormone in the diagnosis of Cushing's syndrome. European Journal of Endocrinology, 2006, 155, S93-S98.	1.9	10

#	Article	IF	CITATIONS
91	Global Inequalities in Paediatric Endocrine Practice: Statement of Minimal Acceptable Care. Hormone Research in Paediatrics, 2006, 65, 111-113.	0.8	5
92	Cushing's Disease in Children and Adolescents: 20 Years of Experience in a Single Neurosurgical Center. Neurosurgery, 2005, 57, 281-285.	0.6	103
93	Final adult height and body mass index after cure of paediatric Cushing's disease. Clinical Endocrinology, 2005, 62, 466-472.	1.2	76
94	IGFs and IGFBPs in CH Insensitivity. , 2005, 9, 100-106.		24
95	Factors influencing cure by transsphenoidal selective adenomectomy in paediatric Cushing's disease. European Journal of Endocrinology, 2005, 152, 825-833.	1.9	65
96	Novel Growth Hormone Receptor Mutation in a Chinese Patient with Laron Syndrome. Journal of Pediatric Endocrinology and Metabolism, 2005, 18, 209-13.	0.4	5
97	Efficient Short-Term Control of Hypercortisolaemia by Low-Dose Etomidate in Severe Paediatric Cushing's Disease. Hormone Research in Paediatrics, 2005, 64, 140-143.	0.8	58
98	Diagnostic and Therapeutic Advances in Growth Hormone Insensitivity. Endocrinology and Metabolism Clinics of North America, 2005, 34, 581-595.	1.2	19
99	Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. Journal of Endocrinological Investigation, 2005, 28, 231-235.	1.8	36
100	Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13260-13265.	3.3	111
101	Growth Hormone (GH) Insensitivity Syndrome due to a GH Receptor Truncated after Box1, Resulting in Isolated Failure of STAT 5 Signal Transduction. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1259-1266.	1.8	65
102	Prepubertal Cushing's Disease Is More Common in Males, But There Is No Increase in Severity at Diagnosis. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3818-3820.	1.8	75
103	Relationships between Serum IGF-1, IGFBP-2, Interleukin-1Beta and Interleukin-6 in Inflammatory Bowel Disease. Hormone Research in Paediatrics, 2004, 61, 159-164.	0.8	78
104	Transitional care of GH deficiency: when to stop GH therapy. European Journal of Endocrinology, 2004, 151 Suppl 1, S61-S65.	1.9	23
105	Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing's syndrome due to primary nodular adrenocortical hyperplasia. Clinical Endocrinology, 2004, 61, 553-559.	1.2	46
106	Successful treatment of childhood-onset Cushing's disease is associated with persistent reduction in growth hormone secretion. Clinical Endocrinology, 2004, 60, 169-174.	1.2	38
107	Standard and low-dose IGF-I generation tests and spontaneous growth hormone secretion in children with idiopathic short stature. Clinical Endocrinology, 2004, 60, 163-168.	1.2	46
108	Therapeutic applications of the insulin-like growth factors. Growth Hormone and IGF Research, 2004, 14, 301-308.	0.5	29

#	Article	IF	CITATIONS
109	The Effect of Cessation of Growth Hormone (GH) Therapy on Bone Mineral Accretion in GH-Deficient Adolescents at the Completion of Linear Growth. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 1658-1663.	1.8	101
110	Clinical and Endocrine Responses to Pituitary Radiotherapy in Pediatric Cushing's Disease: An Effective Second-Line Treatment. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 34-37.	1.8	89
111	Growth in Disorders of Adrenal Hyperfunction. Hormone Research in Paediatrics, 2002, 58, 39-43.	0.8	24
112	The GH–IGF-I axis in children with idiopathic short stature. Trends in Endocrinology and Metabolism, 2002, 13, 325-330.	3.1	40
113	Spontaneous growth hormone secretory characteristics in children with partial growth hormone insensitivity. Clinical Endocrinology, 2002, 57, 357-361.	1.2	15
114	Phenotypic variability in growth hormone insensitivity. Journal of Pediatric Endocrinology and Metabolism, 2002, 15 Suppl 5, 1449-50.	0.4	0
115	Pseudoexon Activation as a Novel Mechanism for Disease Resulting in Atypical Growth-Hormone Insensitivity. American Journal of Human Genetics, 2001, 69, 641-646.	2.6	110
116	Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome. Hormone Research in Paediatrics, 2001, 55, 125-130.	0.8	50
117	Delayed puberty and response to testosterone in a rat model of colitis. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2001, 281, R1483-R1491.	0.9	43
118	Growth Hormone Insensitivity: Pathophysiology, Diagnosis, Clinical Variation and Future Perspectives. Hormone Research in Paediatrics, 2001, 55, 32-35.	0.8	32
119	Relative Contributions of Inferior Petrosal Sinus Sampling and Pituitary Imaging in the Investigation of Children and Adolescents with ACTH-Dependent Cushing's Syndrome. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5711-5714.	1.8	78
120	Growth Hormone Therapy and Growth in Children with Noonan's Syndrome: Results of 3 Years' Follow-Up*. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1953-1956.	1.8	58
121	Cushing's Disease in Childhood: Presentation, Investigation, Treatment and Long-Term Outcome. Hormone Research in Paediatrics, 2001, 55, 24-30.	0.8	51
122	Analysis of the intracellular signalling domain of the human growth hormone receptor in children with idiopathic short stature. Clinical Endocrinology, 2000, 52, 463-469.	1.2	18
123	The combined pituitary function test is not indicated in the routine investigation of short stature. Clinical Endocrinology, 2000, 52, 679-679.	1.2	1
124	Effects of Insulin-Like Growth Factor I (IGF-I) Therapy on Body Composition and Insulin Resistance in IGF-I Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 1407-1411.	1.8	98
125	Linear Growth and Final Height after Treatment for Cushing's Disease in Childhood. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 3262-3265.	1.8	71

#	Article	IF	CITATIONS
127	Effects of Recombinant Human Insulin-Like Growth Factor I (IGF-I) Therapy on the Growth Hormone-IGF System of a Patient with a Partial IGF-I Gene Deletion. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1611-1616.	1.8	67
128	Androgen secreting adrenocortical tumours. Archives of Disease in Childhood, 1999, 80, 46-50.	1.0	51
129	Long-Term Treatment of Growth Hormone Insensitivity Syndrome with IGF-I. Hormone Research in Paediatrics, 1999, 51, 128-134.	0.8	92
130	Growth response to rhIGF-I 80â€∫μg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype. Clinical Endocrinology, 1999, 51, 787-792.	1.2	29
131	Growth in Crohn's disease. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 89-92.	0.7	117
132	Growth hormone insensitivity: a proposed revised classification. Acta Paediatrica, International Journal of Paediatrics, 1999, 88, 147-147.	0.7	55
133	Defects of the growth hormonereceptor and their clinical implications. Growth Hormone and IGF Research, 1999, 9, 57-61.	0.5	16
134	Luteinizing hormone secreting adrenal tumour as a cause of precocious puberty. Clinical Endocrinology, 1998, 48, 367-372.	1.2	6
135	Normal final height and apparent cure after pituitary irradiation for Cushing's disease in childhood: long-term follow-up of anterior pituitary function. Clinical Endocrinology, 1998, 48, 663-667.	1.2	6
136	Changes in serum IGFâ€I and IGFBPâ€3 concen_trations during the IGFâ€I generation test performed prospectively in children with short stature. Clinical Endocrinology, 1998, 48, 719-724.	1.2	39
137	Responsiveness of IGF-I and IGFBP-3 to therapeutic intervention in children and adolescents with Crohn's disease. Clinical Endocrinology, 1998, 49, 483-489.	1.2	92
138	Phenotype: Genotype Relationships in Growth Hormone Insensitivity Syndrome1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 3529-3535.	1.8	137
139	Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet, The, 1997, 350, 1199-1204.	6.3	92
140	Insulinâ€like growth factor I gene deletion causing intrauterine growth retardation and severe short stature. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 39-45.	0.7	112
141	When and how to transfer patients from paediatric to adult endocrinologists: experience from St Bartholomew's Hospital, London. Acta Paediatrica, International Journal of Paediatrics, 1997, 86, 127-128.	0.7	9
142	Intrauterine Growth Retardation and Postnatal Growth Failure Associated with Deletion of the Insulin-Like Growth Factor I Gene. New England Journal of Medicine, 1996, 335, 1363-1367.	13.9	1,002
143	Cushing's disease in childhood. Trends in Endocrinology and Metabolism, 1996, 7, 213-216.	3.1	27
144	Laron syndrome: typical and atypical forms. Bailliere's Clinical Endocrinology and Metabolism, 1996, 10, 371-387.	1.0	35

9

#	Article	IF	CITATIONS
145	Magnetic resonance imaging of adrenocortical adenomas in childhood: Correlation with computed tomography and ultrasound. Pediatric Radiology, 1996, 26, 794-799.	1.1	23
146	The investigation of growth hormone insensitivity. Clinical Endocrinology, 1996, 45, 257-260.	1.2	8
147	A homozygous splice site mutation affecting the intracellular domain of the growth hormone (CH) receptor resulting in Laron syndrome with elevated CH-binding protein Journal of Clinical Endocrinology and Metabolism, 1996, 81, 1686-1690.	1.8	115
148	The short-term effects of growth hormone therapy on height velocity and cardiac ventricular wall thickness in children with Noonan's syndrome Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2291-2297.	1.8	67
149	Recombinant IGF-I therapy in insulin-dependent diabetes mellitus. Diabetes and Metabolism, 1996, 22, 257-60.	1.4	4
150	Growth hormone insensitivity syndromes. Acta Paediatrica, International Journal of Paediatrics, 1995, 84, 87-90.	0.7	6
151	Investigation, management and therapeutic outcome in 12 cases of childhood and adolescent Cushing's syndrome. Clinical Endocrinology, 1995, 43, 19-28.	1.2	97
152	The â€~dawn phenomenon' in adolescents with insulin dependent diabetes mellitus: possible contribution of insulin-like growth factor binding protein-1. Clinical Endocrinology, 1995, 43, 567-574.	1.2	28
153	Insulin-Like Growth Factor I Improves Height in Growth Hormone Insensitivity: Two Years' Results. Hormone Research, 1995, 44, 253-264.	1.8	93
154	Improvement of diagnostic criteria in growth hormone insensitivity syndrome: solutions and pitfalls. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 117-124.	0.7	112
155	Effects of recombinant insulin-like growth factor I on craniofacial morphology in growth hormone insensitivity. Acta Paediatrica, International Journal of Paediatrics, 1994, 83, 140-141.	0.7	22
156	Growth Hormone Insensitivity Syndrome (GHIS): Clinical Presentation and Effects of Treatment with Recombinant Human Insulin-like Growth Factor I (rhIGF-I) European Experience. Clinical Pediatric Endocrinology, 1994, 3, 115-121.	0.4	0
157	The Clinical and Endocrine Spectrum of Growth Hormone Insensitivity Syndrome (GHIS). Clinical Pediatric Endocrinology, 1994, 3, 245-245.	0.4	0
158	Acceleration of pubertal development following pituitary radiotherapy for Cushing's disease. Clinical Oncology, 1993, 5, 393-394.	0.6	21
159	Transsphenoidal resection in Cushing's disease: undetectable serum cortisol as the definition of successful treatment. Clinical Endocrinology, 1993, 38, 73-78.	1.2	260
160	The effect of recombinant human insulin-like growth factor-I treatment on growth hormone secretion in two subjects with growth hormone insensitivity (Laron syndrome). Clinical Endocrinology, 1993, 39, 119-122.	1.2	30
161	Classification of growth hormone insensitivity syndrome. Journal of Pediatrics, 1993, 122, 241.	0.9	91

162 Clinical features and endocrine status in patients with growth hormone insensitivity (Laron) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 Td

#	Article	IF	CITATIONS
163	Clinical features and endocrine status in patients with growth hormone insensitivity (Laron) Tj ETQq1 1 0.784314	4 rg₿T /Ο\ ₽.₿	verlock 10 Tf 149
164	The insulin-like growth factor (IGF)-binding proteins and IGF bioactivity in Laron-type dwarfism Journal of Clinical Endocrinology and Metabolism, 1992, 74, 56-63.	1.8	52
165	Growth patterns after surgery for virilising adrenocortical adenoma Archives of Disease in Childhood, 1992, 67, 234-236.	1.0	19
166	Insulin and Growth Factors Adaptation to Normal Puberty. Hormone Research, 1992, 37, 70-73.	1.8	15
167	Insulin-like growth factors and their binding proteins in patients with growth hormone receptor deficiency: suggestions for new diagnostic criteria. The Kabi Pharmacia Study Group on Insulin-like Growth Factor I Treatment in Growth Hormone Insensitivity Syndromes. Acta Paediatrica, International lournal of Paediatrics. Supplement. 1992. 383. 125-6.	1.0	5
168	Clinical Spectrum of the Syndrome of Growth Hormone Insensitivity. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 87-90.	0.7	8
169	Noonan's Syndrome: Abnormalities of the Growth Hormone/IGF-I Axis and the Response to Treatment with Human Biosynthetic Growth Hormone. Acta Paediatrica, International Journal of Paediatrics, 1991, 80, 446-450.	0.7	65
170	GONADAL NEOPLASIA AND ABNORMAL SEXUAL DIFFERENTIATION. Clinical Endocrinology, 1990, 32, 519-534.	1.2	93
171	Relationship between Insulin, Insulin-Like Growth Factor I, and Dehydroepiandrosterone Sulfate Concentrations During Childhood, Puberty, and Adult Life*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 932-937.	1.8	132
172	Clinical presentation, growth, and pubertal development in Addison's disease Archives of Disease in Childhood, 1985, 60, 925-928.	1.0	20
173	Adherence to r-hGH Therapy in Pediatric Growth Hormone Deficiency: Current Perspectives on How Patient-Generated Data Will Transform r-hGH Treatment Towards Integrated Care. Patient Preference and Adherence, 0, Volume 16, 1663-1671.	0.8	6